DashboardAll companies
Run this on your own research
Healthcare · Drug Manufacturers - General

Gilead Sciences Inc.

GILDNASDAQ$156.04−$1.15 (−0.73%)Market closed

Price Chart

Daily

Key facts

Market Cap
$193.96B
P/E
22.8x
P/B
8.55x
ROE
40.5%

Gilead Sciences Inc.

Healthcare · Drug Manufacturers - General · FY 2025

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.

CEO
Mr. Daniel P. O'Day
Employees
17,600
Website
gilead.com

Company Statistics

Valuation

P/E
22.8x
P/B
8.55x
P/S
6.59x
EV/EBITDA
14.3x
P/FCF
20.5x

Margins

Gross
78.8%
EBITDA
50.3%
Operating
39.7%
Pre-Tax
33.3%
Net
28.9%

Returns

ROA
14.4%
ROE
40.5%
ROIC
18.3%

Growth (CAGR)

Rev 3Yr
2.6%
Rev 5Yr
3.6%
Op Inc 3Yr
2.2%
Net Inc 3Yr
23.1%

Financial Health

Cash & Cash Equivalents
$7.56B
Net Debt
$28.84B
Debt/Equity
161.0%
Interest Cov
—

Profile

Revenue
$29.44B
Shares Out
—
Public markets · Korea, US, Japanalpha-lenz.com · Core by Treasurer
Gilead Sciences Inc. (GILD) Stock Forecast 2026 $156.04 — Price, Financials & Analyst Targets | AlphaLenz